Cargando…

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers

AIM: We provide a descriptive statistical analysis of baseline characteristics and the clinical course of a large real-life cohort of brain metastases (BM) patients. METHODS: We performed a retrospective chart review for patients treated for BM of solid cancers at the Medical University of Vienna be...

Descripción completa

Detalles Bibliográficos
Autores principales: Berghoff, Anna S, Schur, Sophie, Füreder, Lisa M, Gatterbauer, Brigitte, Dieckmann, Karin, Widhalm, Georg, Hainfellner, Johannes, Zielinski, Christoph C, Birner, Peter, Bartsch, Rupert, Preusser, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070252/
https://www.ncbi.nlm.nih.gov/pubmed/27843591
http://dx.doi.org/10.1136/esmoopen-2015-000024
_version_ 1782461107215007744
author Berghoff, Anna S
Schur, Sophie
Füreder, Lisa M
Gatterbauer, Brigitte
Dieckmann, Karin
Widhalm, Georg
Hainfellner, Johannes
Zielinski, Christoph C
Birner, Peter
Bartsch, Rupert
Preusser, Matthias
author_facet Berghoff, Anna S
Schur, Sophie
Füreder, Lisa M
Gatterbauer, Brigitte
Dieckmann, Karin
Widhalm, Georg
Hainfellner, Johannes
Zielinski, Christoph C
Birner, Peter
Bartsch, Rupert
Preusser, Matthias
author_sort Berghoff, Anna S
collection PubMed
description AIM: We provide a descriptive statistical analysis of baseline characteristics and the clinical course of a large real-life cohort of brain metastases (BM) patients. METHODS: We performed a retrospective chart review for patients treated for BM of solid cancers at the Medical University of Vienna between 1990 and 2011. RESULTS: We identified a total of 2419 BM patients (50.5% male, 49.5% female, median age 59 years). The primary tumour was lung cancer in 43.2%, breast cancer in 15.7%, melanoma in 16.4%, renal cell carcinoma in 9.1%, colorectal cancer in 9.3% and unknown in 1.4% of cases. Rare tumour types associated with BM included genitourinary cancers (4.1%), sarcomas (0.7%). gastro-oesophageal cancer (0.6%) and head and neck cancers (0.2%). 48.7% of patients presented with a singular BM, 27.7% with 2–3 and 23.5% with >3 BM. Time from primary tumour to BM diagnosis was shortest in lung cancer (median 11 months; range 1–162) and longest in breast cancer (median 44 months; 1–443; p<0.001). Multiple BM were most frequent in breast cancer (30.6%) and least frequent in colorectal cancer (8.5%; p<0.001). Patients with breast cancer had the longest median overall survival times (8 months), followed by patients with lung cancer (7 months), renal cell carcinoma (7 months), melanoma (5 months) and colorectal cancer (4 months; p<0.001; log rank test). Recursive partitioning analysis and graded prognostic assessment scores showed significant correlation with overall survival (both p<0.001, log rank test). Evaluation of the disease status in the past 2 months prior to patient death showed intracranial progression in 35.9%, extracranial progression in 27.5% and combined extracranial and intracranial progression in 36.6% of patients. CONCLUSIONS: Our data highlight the heterogeneity in presentation and clinical course of BM patients in the everyday clinical setting and may be useful for rational planning of clinical studies.
format Online
Article
Text
id pubmed-5070252
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50702522016-11-14 Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers Berghoff, Anna S Schur, Sophie Füreder, Lisa M Gatterbauer, Brigitte Dieckmann, Karin Widhalm, Georg Hainfellner, Johannes Zielinski, Christoph C Birner, Peter Bartsch, Rupert Preusser, Matthias ESMO Open Original Article AIM: We provide a descriptive statistical analysis of baseline characteristics and the clinical course of a large real-life cohort of brain metastases (BM) patients. METHODS: We performed a retrospective chart review for patients treated for BM of solid cancers at the Medical University of Vienna between 1990 and 2011. RESULTS: We identified a total of 2419 BM patients (50.5% male, 49.5% female, median age 59 years). The primary tumour was lung cancer in 43.2%, breast cancer in 15.7%, melanoma in 16.4%, renal cell carcinoma in 9.1%, colorectal cancer in 9.3% and unknown in 1.4% of cases. Rare tumour types associated with BM included genitourinary cancers (4.1%), sarcomas (0.7%). gastro-oesophageal cancer (0.6%) and head and neck cancers (0.2%). 48.7% of patients presented with a singular BM, 27.7% with 2–3 and 23.5% with >3 BM. Time from primary tumour to BM diagnosis was shortest in lung cancer (median 11 months; range 1–162) and longest in breast cancer (median 44 months; 1–443; p<0.001). Multiple BM were most frequent in breast cancer (30.6%) and least frequent in colorectal cancer (8.5%; p<0.001). Patients with breast cancer had the longest median overall survival times (8 months), followed by patients with lung cancer (7 months), renal cell carcinoma (7 months), melanoma (5 months) and colorectal cancer (4 months; p<0.001; log rank test). Recursive partitioning analysis and graded prognostic assessment scores showed significant correlation with overall survival (both p<0.001, log rank test). Evaluation of the disease status in the past 2 months prior to patient death showed intracranial progression in 35.9%, extracranial progression in 27.5% and combined extracranial and intracranial progression in 36.6% of patients. CONCLUSIONS: Our data highlight the heterogeneity in presentation and clinical course of BM patients in the everyday clinical setting and may be useful for rational planning of clinical studies. BMJ Publishing Group 2016-03-16 /pmc/articles/PMC5070252/ /pubmed/27843591 http://dx.doi.org/10.1136/esmoopen-2015-000024 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Original Article
Berghoff, Anna S
Schur, Sophie
Füreder, Lisa M
Gatterbauer, Brigitte
Dieckmann, Karin
Widhalm, Georg
Hainfellner, Johannes
Zielinski, Christoph C
Birner, Peter
Bartsch, Rupert
Preusser, Matthias
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
title Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
title_full Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
title_fullStr Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
title_full_unstemmed Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
title_short Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
title_sort descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070252/
https://www.ncbi.nlm.nih.gov/pubmed/27843591
http://dx.doi.org/10.1136/esmoopen-2015-000024
work_keys_str_mv AT berghoffannas descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT schursophie descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT furederlisam descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT gatterbauerbrigitte descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT dieckmannkarin descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT widhalmgeorg descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT hainfellnerjohannes descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT zielinskichristophc descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT birnerpeter descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT bartschrupert descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers
AT preussermatthias descriptivestatisticalanalysisofareallifecohortof2419patientswithbrainmetastasesofsolidcancers